Naoki Izawa

642 total citations
58 papers, 363 citations indexed

About

Naoki Izawa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Naoki Izawa has authored 58 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 26 papers in Surgery. Recurrent topics in Naoki Izawa's work include Gastric Cancer Management and Outcomes (28 papers), Colorectal Cancer Treatments and Studies (25 papers) and Cancer Genomics and Diagnostics (12 papers). Naoki Izawa is often cited by papers focused on Gastric Cancer Management and Outcomes (28 papers), Colorectal Cancer Treatments and Studies (25 papers) and Cancer Genomics and Diagnostics (12 papers). Naoki Izawa collaborates with scholars based in Japan, United States and United Kingdom. Naoki Izawa's co-authors include Takako Eguchi Nakajima, Yu Sunakawa, Takuro Mizukami, Narikazu Boku, Yoshiki Horie, Fumio Itoh, Tomohiro Nishina, Kei Muro, Takeharu Yamanaka and Yutaka Kawakami and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Naoki Izawa

47 papers receiving 357 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Naoki Izawa Japan	9	189	132	109	83	44	58	363
Ariel E. Birnbaum United States	8	118 0.6×	119 0.9×	60 0.6×	60 0.7×	25 0.6×	25	284
Jean Philippe Metges France	8	224 1.2×	124 0.9×	85 0.8×	110 1.3×	19 0.4×	23	343
Keita Uchino Japan	12	215 1.1×	151 1.1×	59 0.5×	86 1.0×	42 1.0×	40	357
Maria Antista Italy	10	205 1.1×	94 0.7×	69 0.6×	61 0.7×	13 0.3×	26	300
E. Goode United Kingdom	7	177 0.9×	106 0.8×	51 0.5×	108 1.3×	25 0.6×	12	325
Naoki Ishiwa Japan	11	152 0.8×	173 1.3×	125 1.1×	108 1.3×	24 0.5×	27	424
Yakup Bozkaya Türkiye	10	172 0.9×	84 0.6×	79 0.7×	33 0.4×	18 0.4×	35	285
Andrea Hinsch Germany	14	127 0.7×	135 1.0×	141 1.3×	155 1.9×	13 0.3×	26	391
Jung Shin Lee South Korea	10	313 1.7×	321 2.4×	64 0.6×	73 0.9×	49 1.1×	18	477
Shinji Endo Japan	12	130 0.7×	96 0.7×	93 0.9×	109 1.3×	60 1.4×	28	350

Countries citing papers authored by Naoki Izawa

Since Specialization

Citations

This map shows the geographic impact of Naoki Izawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoki Izawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoki Izawa more than expected).

Fields of papers citing papers by Naoki Izawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoki Izawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoki Izawa. The network helps show where Naoki Izawa may publish in the future.

Co-authorship network of co-authors of Naoki Izawa

This figure shows the co-authorship network connecting the top 25 collaborators of Naoki Izawa. A scholar is included among the top collaborators of Naoki Izawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoki Izawa. Naoki Izawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ooki, Akira, Kei Muro, Kazumi Nishino, et al.. (2024). Phase 1b study of futibatinib plus pembrolizumab with or without chemotherapy in patients with esophageal carcinoma: Updated results of antitumor activity.. Journal of Clinical Oncology. 42(16_suppl). 4047–4047.

Kotani, Daisuke, Atsuo Takashima, Takeshi Kato, et al.. (2024). Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program. Clinical Colorectal Cancer. 23(2). 174–182.e6. 3 indexed citations

Yamamoto, Hiroyuki, Hiroyuki Arai, Ritsuko Oikawa, et al.. (2024). The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling. Targeted Oncology. 19(3). 459–471.

Matsubara, Yuki, Daisuke Kotani, Yoshinori Kagawa, et al.. (2023). BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer.. Journal of Clinical Oncology. 41(4_suppl). TPS271–TPS271.

Mitani, Seiichiro, Yosuke Kito, Kentaro Kawakami, et al.. (2023). Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study. Targeted Oncology. 18(5). 707–715. 2 indexed citations

Mizukami, Takuro, Hiroyuki Takeda, Kumiko Umemoto, et al.. (2023). Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer. Frontiers in Oncology. 13. 1110236–1110236. 2 indexed citations

Saeki, Hiroshi, Hideo Uehara, Yoshiko Matsuda, et al.. (2023). Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients. International Journal of Clinical Oncology. 28(9). 1166–1175.

Suyama, Koichi, Hiroo Katsuya, Naoki Izawa, et al.. (2022). A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701. European Journal of Cancer. 166. 279–286. 4 indexed citations

Shimizu, Toshio, Takako Eguchi Nakajima, Noboru Yamamoto, et al.. (2022). Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. Investigational New Drugs. 40(5). 1021–1031. 26 indexed citations

10.

Nakamura, Michio, Atsushi Ishiguro, Yasuyuki Kawamoto, et al.. (2022). Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study. BMC Cancer. 22(1). 1322–1322.

11.

Mizukami, Takuro, Hiroyuki Takeda, Yoshiki Horie, et al.. (2021). Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment. Nutrition and Cancer. 74(2). 539–545. 6 indexed citations

12.

Yamamoto, Shun, Kengo Nagashima, Takeshi Kawakami, et al.. (2021). Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. BMC Cancer. 21(1). 1159–1159. 1 indexed citations

13.

Nakajima, Takako Eguchi, Shigenori Kadowaki, Keiko Minashi, et al.. (2020). Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer. Clinical Cancer Research. 27(4). 1029–1036. 63 indexed citations

14.

Izawa, Naoki, Takashi Kawaguchi, Tempei Miyaji, et al.. (2020). Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy. BMJ Open. 10(12). e041737–e041737. 1 indexed citations

15.

Takeda, Hiroyuki, Kumiko Umemoto, Hidefumi Mimura, et al.. (2020). Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report. World Journal of Gastrointestinal Oncology. 12(11). 1364–1371. 1 indexed citations

16.

Sunakawa, Yu, Naoki Izawa, Takuro Mizukami, et al.. (2017). Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy. OncoTargets and Therapy. Volume 10. 4599–4605. 5 indexed citations

17.

Sakamaki, Kentaro, Yosuke Kito, Kentaro Yamazaki, et al.. (2017). Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size. ESMO Open. 2(5). e000275–e000275. 6 indexed citations

18.

Izawa, Naoki, Wenwen Wu, Ko Sato, et al.. (2011). HERC2 Interacts with Claspin and Regulates DNA Origin Firing and Replication Fork Progression. Cancer Research. 71(17). 5621–5625. 39 indexed citations

19.

Izawa, Naoki, Takeshi Sawada, & Fumio Itoh. (2009). Cause of Lower Limb Edema and Hypoproteinemia Diagnosed by Double-Balloon Endoscopy. Gastroenterology. 137(4). e1–e2. 7 indexed citations

20.

Izawa, Naoki, Satoshi Baba, Nobuyuki Matsumoto, et al.. (2008). A case of cholangiolocellular carcinoma of which image findings changed during the time of progression. Kanzo. 49(9). 430–439. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact